Skip to content
Interferences in Lupus testing
11th ECAT International Symposium
Speaker
Titel
Abstract
R. Urbanus
Interferences in Lupus testing
Abstract not available!
The presentation is provided below.
Related items
Analytical Information :
3
Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban
Lupus anticoagulant testing: analyzing fresh samples after a single centrifugation and after a 6-8 hr delay
Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays
Cases :
2
Lupus Anticoagulant-Hypoprothrombinemia Syndrome
Acquired Hemophilia A, case study
ECAT Documents :
42
Vitamin K
Lupus Anticoagulant (LA)
Coumarin
Antiphospholipid antibody solid phase-based assays: problems and proposed solutions for the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome: reply.
Defining a metrologically traceable and sustainable calibration hierarchy of international normalized ratio for monitoring of vitamin K antagonist treatment in accordance with International Organization for Standardization (ISO) 17511:2020 standard: communication from the International Federation of Clinical Chemistry and Laboratory Medicine-SSC/ISTH working group on prothrombin time/international normalized ratio standardization.
International external quality assessment for measurements of direct oral anticoagulants: results and recommendations.
Laboratory assesment of direct and indirect thrombin inhibitors
The results of the workshop on inhibitor testing
The antiphospholipid syndrome: a laboratory phenomenon?
New developments in laboratory tests
Desired tests for monitoring new anticoagulation drugs
An update on new anticoagulation drugs
Lupus Anticoagulant: Remarkable observations in ECAT surveys
Lupus Anticoagulant: Do guidelines work in practice?
Lupus Anticoagulant: Update of the SSC guidelines
Case studies in Thrombophilia
The CLSI & BCSH algorithms for Lupus anticoagulant testing
The SSC algorithm for Lupus testing
Biochemical background of Lupus Anticoagulant
Measurement of new oral anticoagulans
Factor VIII inhibitor testing – a way to comparable test results
The pathophysiology of Lupus Anticoagulant and the consequences for the laboratory diagnostics
The new CLSI guideline on Lupus Anticoagulant testing
ECAT survey results on direct oral anticoagulant testing
Monitoring new oral anticoagulants-Practical approach
The future of anticoagulation
Thrombosis webinar 2021, Antiphospholipid Antibody, Anticoagulation bridging
Lupus Anticoagulants webinar 2023
Medical device thrombosis
Developmental haemostasis: consequences for clinical practice
Results of ECAT EQA programme on DOACS
Interference of DOACS in coagulation tests
Guidance for laboratory testing of DOACS
The use of snake venoms in the coagulation laboratory
Thrombotic APS pathophysiology: consequences for laboratory diagnosis
Antiphospholipid Antibody Assay results and clinical implications
Follow-up of LA positieve patients
When Haemostasis Assays Mislead
Sinus thrombosis, past, present and future
COVID-19 and the role of the haemostasis laboratory
Impact of COVID-19 pandemic on the quality of test output in haemostasis laboratories
Antiphospholipid antibody solid phase–based assays: problems and proposed solutions for the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome
Guidelines :
2
ICSH Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
Update Recommendations for Laboratory Measurement of Direct Oral Anticoagulants, ICSH recommendations
Quality Issues :
1
External quality assessment for Rivaroxaban and Dabigatran
Questions or suggestions?
Clotpedia Support Form
Submit
Success
